Translating Next-Generation Science Into Transformative Gene Therapies Learn About Our Programs

News & Events Press Releases March 25, 2026 Encoded Therapeutics Announces FDA Alignment, Initiation of Pivotal Study, and ASGCT Presidential Symposium Presentation of ETX101 in Dravet …

Mar 25, 2026 · Encoded Therapeutics Announces FDA Alignment, Initiation of Pivotal Study, and ASGCT Presidential Symposium Presentation of ETX101 in Dravet Syndrome FDA alignment …

Data from observational studies and clinical trials, which depend on volunteer participants, form the foundation of regulatory authorities’ decisions to approve new therapies for broader use.

Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Our diversity – whether gender, ethnicity, sexual …

Contact Directory Patients Community and Clinical Trials patientadvocacy@encoded.com Healthcare Providers medinfo@encoded.com Media communications@encoded.com Finance/Accounting …

Encoded Therapeutics Presents Preclinical Data Across its Gene Therapy Portfolio at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) Four presentations highlight …

Jan 12, 2026 · Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome – Designation recognizes the potential of ETX101 …

Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook POLARIS program, launched in …

Encoded is building an internally developed pipeline of best- and potentially first-in-class therapies focused on pediatric central nervous system (CNS) disorders.